These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15037729)

  • 1. New treatment alternatives for Duchenne and Becker muscular dystrophy.
    Restrepo S
    Neurology; 2004 Mar; 62(6):E10. PubMed ID: 15037729
    [No Abstract]   [Full Text] [Related]  

  • 2. Pilot trial of albuterol in Duchenne and Becker muscular dystrophy.
    Fowler EG; Graves MC; Wetzel GT; Spencer MJ
    Neurology; 2004 Mar; 62(6):1006-8. PubMed ID: 15037714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy.
    Skura CL; Fowler EG; Wetzel GT; Graves M; Spencer MJ
    Neurology; 2008 Jan; 70(2):137-43. PubMed ID: 17942817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot trial of albuterol in spinal muscular atrophy.
    Kinali M; Mercuri E; Main M; De Biasia F; Karatza A; Higgins R; Banks LM; Manzur AY; Muntoni F
    Neurology; 2002 Aug; 59(4):609-10. PubMed ID: 12196659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preserving function in Duchenne dystrophy with long-term pulse prednisone therapy.
    Carter GT; McDonald CM
    Am J Phys Med Rehabil; 2000; 79(5):455-8. PubMed ID: 10994887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prednisone 10 days on/10 days off in patients with Duchenne muscular dystrophy.
    Straathof CS; Overweg-Plandsoen WC; van den Burg GJ; van der Kooi AJ; Verschuuren JJ; de Groot IJ
    J Neurol; 2009 May; 256(5):768-73. PubMed ID: 19306039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroids in Duchenne muscular dystrophy: a reappraisal.
    Wong BL; Christopher C
    J Child Neurol; 2002 Mar; 17(3):183-90. PubMed ID: 12026233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China.
    Hu J; Ye Y; Kong M; Hong S; Cheng L; Wang Q; Qin J; Zou L; Jiang L
    Muscle Nerve; 2015 Dec; 52(6):1001-7. PubMed ID: 25809413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly oral prednisolone improves survival and strength in male mdx mice.
    Keeling RM; Golumbek PT; Streif EM; Connolly AM
    Muscle Nerve; 2007 Jan; 35(1):43-8. PubMed ID: 16969833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
    Moxley RT; Ashwal S; Pandya S; Connolly A; Florence J; Mathews K; Baumbach L; McDonald C; Sussman M; Wade C; ;
    Neurology; 2005 Jan; 64(1):13-20. PubMed ID: 15642897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prednisone for Duchenne muscular dystrophy.
    Dubowitz V
    Lancet Neurol; 2005 May; 4(5):264. PubMed ID: 15847833
    [No Abstract]   [Full Text] [Related]  

  • 12. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early prednisone treatment in Duchenne muscular dystrophy.
    Merlini L; Cicognani A; Malaspina E; Gennari M; Gnudi S; Talim B; Franzoni E
    Muscle Nerve; 2003 Feb; 27(2):222-7. PubMed ID: 12548530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal height and weight in a series of ambulant Duchenne muscular dystrophy patients using the 10 day on/10 day off prednisone regimen.
    ten Dam K; de Groot IJ; Noordam C; van Alfen N; Hendriks JC; Sie LT
    Neuromuscul Disord; 2012 Jun; 22(6):500-4. PubMed ID: 22390890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetics and emerging treatments for Duchenne and Becker muscular dystrophy.
    Wein N; Alfano L; Flanigan KM
    Pediatr Clin North Am; 2015 Jun; 62(3):723-42. PubMed ID: 26022172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deflazacort for the treatment of Duchenne Dystrophy: a systematic review.
    Campbell C; Jacob P
    BMC Neurol; 2003 Sep; 3():7. PubMed ID: 12962544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. FSH-DY Group.
    Kissel JT; McDermott MP; Natarajan R; Mendell JR; Pandya S; King WM; Griggs RC; Tawil R
    Neurology; 1998 May; 50(5):1402-6. PubMed ID: 9595995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial.
    Beenakker EA; Fock JM; Van Tol MJ; Maurits NM; Koopman HM; Brouwer OF; Van der Hoeven JH
    Arch Neurol; 2005 Jan; 62(1):128-32. PubMed ID: 15642859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hand weakness in Duchenne muscular dystrophy and its relation to physical disability.
    Mattar FL; Sobreira C
    Neuromuscul Disord; 2008 Mar; 18(3):193-8. PubMed ID: 18207403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.